San Diego Biotech’s ‘Molecular Glue’ Hits First Kidney Cancer Patient
San Diego biotech Neomorph has dosed the first patient in a Phase 1/2 trial of NEO‑811, a molecular glue for clear‑cell kidney cancer, after landing multibillion‑dollar pharma deals. Early safety and activity readouts will be the near‑term test.












